7TM Pharma successfully conducts clinical Phase I trial of its first in class peripheral CB1 receptor antagonist TM38837 demonstrating restriction from the human CNS

Press Release Thursday, November 11, 2010

7TM Pharma completes positron emission tomography preclinical research program to successfully demonstrate peripheral restriction of its CB1 receptor antagonist TM38837

Press Release Monday, July 12, 2010

7TM Pharma receives milestone payment from asthma and allergy collaboration

Press Release Wednesday, May 26, 2010